000864115 001__ 864115
000864115 005__ 20230207130530.0
000864115 0247_ $$2CORDIS$$aG:(EU-Grant)826421$$d826421
000864115 0247_ $$2CORDIS$$aG:(EU-Call)H2020-SC1-DTH-2018-1$$dH2020-SC1-DTH-2018-1
000864115 0247_ $$2originalID$$acorda__h2020::826421
000864115 035__ $$aG:(EU-Grant)826421
000864115 150__ $$aPersonalized Recommendations for Neurodegenerative Disease$$y2018-12-01 - 2023-05-31
000864115 371__ $$aCODEBOX COMPUTER-DIENSTE GMBH$$dGermany$$ehttp://www.codebox.de$$vCORDIS
000864115 371__ $$aEODYNE SYSTEMS SL$$bEODYNE SYSTEMS$$dSpain$$ehttp://www.eodyne.com$$vCORDIS
000864115 371__ $$aTP21 GMBH$$bTP21$$dGermany$$ehttp://www.tp21.com$$vCORDIS
000864115 371__ $$aCODEMART SRL$$bCODEMART$$dRomania$$ehttp://www.codemart.ro$$vCORDIS
000864115 371__ $$aINSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE$$bICM$$dFrance$$ehttp://www.icm-institute.org/$$vCORDIS
000864115 371__ $$aForschungszentrum Jülich$$bForschungszentrum Jülich$$dGermany$$ehttps://www.ptj.de/$$vCORDIS
000864115 371__ $$aUniversitätszahnklinik Wien$$bUniversitätszahnklinik Wien$$dAustria$$ehttps://www.unizahnklinik-wien.at/en/$$vCORDIS
000864115 371__ $$aUniversity of Genoa$$bUniGe$$dItaly$$ehttp://www.unige.it/$$vCORDIS
000864115 371__ $$aFUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA$$bIBEC$$dSpain$$ehttp://www.ibecbarcelona.eu$$vCORDIS
000864115 371__ $$aAix-Marseille University$$bAMU$$dFrance$$ehttp://www.univ-amu.fr/$$vCORDIS
000864115 371__ $$aTHE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD$$bUOXF$$dUnited Kingdom$$ehttp://www.ox.ac.uk$$vCORDIS
000864115 371__ $$aAlzheimer Europe$$bAE$$dLuxembourg$$ehttp://www.alzheimer-europe.org/$$vCORDIS
000864115 371__ $$aHELSINGIN YLIOPISTO$$dFinland$$ehttp://www.helsinki.fi$$vCORDIS
000864115 371__ $$aINSTITUT NATIONAL DE RECHERCHE ENINFORMATIQUE ET AUTOMATIQUE$$bINRIA$$dFrance$$ehttp://www.inria.fr$$vCORDIS
000864115 371__ $$aComplutense University of Madrid$$bComplutense University of Madrid$$dSpain$$ehttps://www.ucm.es/english$$vCORDIS
000864115 371__ $$aFRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.$$bFraunhofer$$dGermany$$ehttp://www.fraunhofer.de$$vCORDIS
000864115 371__ $$aCharité Universitätsmedizin Berlin$$dGermany$$ehttps://www.charite.de/charite/$$vCORDIS
000864115 372__ $$aH2020-SC1-DTH-2018-1$$s2018-12-01$$t2023-05-31
000864115 450__ $$aVirtualBrainCloud$$wd$$y2018-12-01 - 2023-05-31
000864115 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000864115 680__ $$aThe annual worldwide cost of Alzheimer’s dementia was 777.81 billion Euro in 2015. This number will rise to 7.41 trillion Euro in 2050. Early diagnosis would save up to $7.9 trillion in medical and care costs by 2050 in the US alone. However, the emergent pathology is highly variable across people, necehighly variable across people, necessitating individualized diagnostics and interventions.  The VirtualBrainCloud addresses this by bridging the gap between computational neuroscience and subcellular systems biology, integrating both research streams into a unifying computational model that supports personalized diagnostics and treatments in NDD. TheVirtualBrainCloud not only integrates existing software tools, it also merges the efforts of two big EU initiatives, namely The Virtual Brain large scale simulation platform of the EU Flagship Human Brain Project and IMI-EPAD initiative (European prevention of Alzheimer’s dementia consortium). VirtualBrainCloud will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalized diagnostics and treatments in NDD. The EU PRACE (Partnership for Advanced Computing in Europe) initiative, will provide the required computing infrastructure. The VirtualBrainCloud will develop robust solutions for legal and ethical matters by interacting with EU projects such as European Open Science Cloud (EOSC), ‘cloud4health’, Alzheimer’s Europe patient organizations and ELIXIR, an organization that manages and safeguards EU research data. Our software developers have already produced highly successful brain simulation and clinical decision support tools. The resulting software will be a cloud based computational modeling system that is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression and serves as Precision Decision Support System.
000864115 909CO $$ooai:juser.fz-juelich.de:864115$$pauthority$$pauthority:GRANT
000864115 970__ $$aoai:dnet:corda__h2020::d75aa306d862f7b8ce59ee1a785df630
000864115 980__ $$aG
000864115 980__ $$aCORDIS
000864115 980__ $$aAUTHORITY